Skip to content

Randomized trial of micronutrient-fortified salt in women in Southern India

A Randomized Trial of Quadruple Fortified Salt for Anemia and Birth Defects Prevention in Southern India - QFS

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/066208
Enrollment
1000
Registered
2024-04-24
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: DFS + Folic acid: Salt fortified with iron, iodine, and folic acid Intervention2: DFS + Vitamin B12: Salt fortified with iron, iodine, and vitamin B12 Intervention3: Quadruple-Fortified

Sponsors

Cornell University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Women between 18 and 49 years of age - Healthy - Not pregnant or lactating - Plan to reside in the catchment area of our periconceptional surveillance program for at least two years

Exclusion criteria

Exclusion criteria: - Severe anemia, i.e., Hemoglobin less than 8.0 g/dL - Reported diagnosis of HIV, malaria infection, or active tuberculosis disease - Malabsorption disorders - Stage 2 hypertension, i.e., SBP =140 or DBP =90 mmHg - Glycated hemoglobin, HbA1c =6.5% - Other serious pre-existing medical conditions, active infections, or acute illnesses - Previous pregnancy affected by a neural tube defect - Planning to become pregnant in the next 12 months - Daily micronutrient supplements, i.e., tablets capsules or dispersible tablets =4 times in the past week - Intramuscular or intravenous interventions containing medications or micronutrients in the past 3 months

Design outcomes

Primary

MeasureTime frame
- Red blood cell (RBC) folate and serum folate concentrations, nmol/L - Hemoglobin concentrations, g/dL - Vitamin B12 concentrations, pmol/LTimepoint: Endpoint, i.e., 12 months

Secondary

MeasureTime frame
Anemia, i.e., Hemoglobin less than 12.0 g/dLTimepoint: Endpoint, i.e., 12 months;Folate deficiency and insufficiency, i.e., RBC folate less than 305 nmol/L and less than 748 nmol/LTimepoint: Endpoint, i.e., 12 months;Vitamin B12 deficiency and insufficiency i.e., total vitamin B12 less than 148.0 pmol/L and less than 221.0 pmol/LTimepoint: Endpoint, i.e., 12 months

Countries

India

Contacts

Public ContactDr Prakash Babu Narasimhan

Arogyavaram Medical Center

amc.arogyavaram@gmail.com917569425255

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 6, 2026